tirzepatide surpass cvot 💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What Frias_Tirzepatide: Overview of SURPASS Trials

Common Misconceptions About Semaglutide and Tirzepatide Misconception 1: These medications are a quick fix for weight loss

About the Experts Susie Reiner, Ph.D., is an exercise physiologist and founder of TheoryEx Performance, a scientific consulting agency

Nature Medicine, 28 (10), 2083-2091

Pancreatitis : Stop use and seek medical attention if you experience severe, persistent abdominal pain that may radiate to your back, with or without vomiting

The company operates in more than 20 countries, including Mexico and the United States, and recently strengthened its position through the acquisition of biopharmaceutical company Probiomed, emerging as Mexicos largest biopharmaceutical firm